StockData
Neurogene Inc. logo

Neurogene Inc. (NGNE) stock

NGNENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$23.10−0.20 (-0.86%)

Close on Nov 17, 2026Market cap $462.26MP/E –Yield –

Neurogene ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Neurogene's ebitda for the twelve months ending Jun 30, 2026 was -$118.11M. For fiscal 2025 it was -$100.29M. The highest annual figure on record is -$32.34M in fiscal 2018.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$100.29M–
FY2024Dec 31, 2024-$79.41M–
FY2023Dec 31, 2023-$52.32M–
FY2022Dec 31, 2022-$53.32M–
FY2021Dec 31, 2021-$59.39M–
FY2020Dec 31, 2020-$32.94M–
FY2019Dec 31, 2019-$70.62M–
FY2018Dec 31, 2018-$32.34M–
FY2017Dec 31, 2017-$50.76M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$35.86M–
Q1 FY2026Mar 31, 2026-$32.50M–
Q4 FY2025Dec 31, 2025-$26.75M–
Q3 FY2025Sep 30, 2025-$23.00M–
Q2 FY2025Jun 30, 2025-$25.28M–
Q1 FY2025Mar 31, 2025-$25.17M–
Q4 FY2024Dec 31, 2024-$20.73M–
Q3 FY2024Sep 30, 2024-$21.38M–
Q2 FY2024Jun 30, 2024-$19.33M–
Q1 FY2024Mar 31, 2024-$17.97M–
Q4 FY2023Dec 31, 2023-$13.92M–
Q3 FY2023Sep 30, 2023-$14.42M–
Q2 FY2023Jun 30, 2023-$11.80M–
Q1 FY2023Mar 31, 2023-$12.22M–
Q4 FY2022Dec 31, 2022-$9.67M–
Q3 FY2022Sep 30, 2022-$13.29M–
Q2 FY2022Jun 30, 2022-$15.41M–
Q1 FY2022Mar 31, 2022-$14.95M–
Q4 FY2021Dec 31, 2021-$14.78M–
Q3 FY2021Sep 30, 2021-$15.10M–
Q2 FY2021Jun 30, 2021-$14.81M–
Q1 FY2021Mar 31, 2021-$14.70M–
Q4 FY2020Dec 31, 2020-$12.43M–
Q3 FY2020Sep 30, 2020-$2.06M–
Q2 FY2020Jun 30, 2020-$9.55M–
Q1 FY2020Mar 31, 2020-$8.90M–
Q4 FY2019Dec 31, 2019-$8.20M–
Q3 FY2019Sep 30, 2019-$59.42M–
Q2 FY2019Jun 30, 2019-$387.00K–

More Neurogene figures

See a number that looks wrong?